Pfizer has faced a decline in COVID-related revenues, causing a drop in stock value. However, recent developments suggest a potential rebound, with strong growth in oncology, hematology, and vaccines. Pfizer’s current portfolio is delivering positive results, with total revenue up 10% in the second quarter.

Despite investing in business development, Pfizer remains a reliable dividend stock with a 7.2% yield. The company raised its 2025 adjusted EPS guidance, showcasing confidence in future growth. Analysts rate Pfizer stock as a “Moderate Buy,” with a price target suggesting potential upside. The company’s post-pandemic transformation could lead to significant growth.

Read more at Yahoo Finance: Why the Recovery in Pfizer Stock Could Be Bigger Than Investors Expect